Dmitry Galkin

701 total citations
17 papers, 482 citations indexed

About

Dmitry Galkin is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Dmitry Galkin has authored 17 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 3 papers in Surgery. Recurrent topics in Dmitry Galkin's work include Asthma and respiratory diseases (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers) and Respiratory and Cough-Related Research (9 papers). Dmitry Galkin is often cited by papers focused on Asthma and respiratory diseases (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers) and Respiratory and Cough-Related Research (9 papers). Dmitry Galkin collaborates with scholars based in United States, United Kingdom and Spain. Dmitry Galkin's co-authors include Frank C. Albers, Miguel Bergna, Michael Murphy, Paola Antonini, Bradley E. Chipps, Kenneth R. Chapman, А. Г. Чучалин, Jean Bousquet, Xavier Muñoz and Mark C. Liu and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Allergy and Clinical Immunology and Allergy.

In The Last Decade

Dmitry Galkin

15 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dmitry Galkin United States 9 327 286 72 69 61 17 482
Péter Csonka Finland 9 216 0.7× 165 0.6× 105 1.5× 7 0.1× 18 0.3× 38 317
David Vyles United States 11 106 0.3× 77 0.3× 44 0.6× 50 0.7× 213 3.5× 21 521
Jean Paradis Canada 11 72 0.2× 79 0.3× 45 0.6× 27 0.4× 276 4.5× 26 545
Michael G. Sherenian United States 8 52 0.2× 56 0.2× 18 0.3× 38 0.6× 81 1.3× 19 217
Sally Eyers New Zealand 6 70 0.2× 79 0.3× 75 1.0× 42 0.6× 14 0.2× 8 270
R Wettengel Germany 10 234 0.7× 164 0.6× 35 0.5× 15 0.2× 25 0.4× 43 326
M. Morales Suárez-Varela Spain 9 159 0.5× 224 0.8× 45 0.6× 21 0.3× 76 1.2× 24 342
Komalkirti Apte India 6 106 0.3× 67 0.2× 22 0.3× 23 0.3× 15 0.2× 16 218
Maqbool Qadir Pakistan 9 183 0.6× 31 0.1× 85 1.2× 228 3.3× 4 0.1× 29 438
Peter Bremner Australia 12 455 1.4× 356 1.2× 19 0.3× 18 0.3× 65 1.1× 21 656

Countries citing papers authored by Dmitry Galkin

Since Specialization
Citations

This map shows the geographic impact of Dmitry Galkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitry Galkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitry Galkin more than expected).

Fields of papers citing papers by Dmitry Galkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitry Galkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitry Galkin. The network helps show where Dmitry Galkin may publish in the future.

Co-authorship network of co-authors of Dmitry Galkin

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitry Galkin. A scholar is included among the top collaborators of Dmitry Galkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitry Galkin. Dmitry Galkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Martínez, Fernando J., Alberto Papi, Tobias Welte, et al.. (2024). COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US. International Journal of COPD. Volume 19. 1433–1445. 3 indexed citations
2.
Wen, Fuqiang, Yanmin Wu, Chunyan Xing, et al.. (2024). Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study. COPD Journal of Chronic Obstructive Pulmonary Disease. 21(1). 2425157–2425157.
3.
4.
5.
Liu, Mark C., Bradley E. Chipps, Xavier Muñoz, et al.. (2021). Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respiratory Research. 22(1). 144–144. 22 indexed citations
6.
Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2019). Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration. Journal of Allergy and Clinical Immunology. 143(2). AB102–AB102. 4 indexed citations
7.
Müllerová, Hana, Wilhelmine Meeraus, Dmitry Galkin, Frank C. Albers, & Sarah Landis. (2019). <p>Clinical burden of illness among patients with severe eosinophilic COPD</p>. International Journal of COPD. Volume 14. 741–755. 12 indexed citations
8.
Chapman, Kenneth R., Frank C. Albers, Bradley E. Chipps, et al.. (2019). The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 74(9). 1716–1726. 109 indexed citations
9.
Feldman, Gregory, et al.. (2018). Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease. Chronic Respiratory Disease. 16. 403058124–403058124. 5 indexed citations
10.
Rubin, David, Michael O’Neal, Sophie Bennett, et al.. (2018). Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials. International Journal of COPD. Volume 13. 189–201. 5 indexed citations
11.
Galkin, Dmitry, Mark C. Liu, Bradley E. Chipps, et al.. (2018). Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes. Journal of Allergy and Clinical Immunology. 141(2). AB409–AB409. 12 indexed citations
12.
Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2018). Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Asthma Control, Quality of Life and Lung Function Outcomes. Journal of Allergy and Clinical Immunology. 141(2). AB408–AB408. 6 indexed citations
13.
Kerwin, Edward, Chris Kalberg, Dmitry Galkin, et al.. (2017). Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. International Journal of COPD. Volume 12. 745–755. 29 indexed citations
14.
Kalberg, Chris, Dianne M. O’Dell, Dmitry Galkin, Amy Newlands, & William A. Fahy. (2016). Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Drugs in R&D. 16(2). 217–227. 23 indexed citations
15.
Чучалин, А. Г., Nikolaï Khaltaev, Dmitry Galkin, et al.. (2014). Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD. 9. 963–963. 158 indexed citations
16.
DiSantostefano, Rachael L., Hao Li, David Hinds, Dmitry Galkin, & David Rubin. (2014). Risk of pneumonia with inhaled corticosteroid/long-acting &beta;2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. International Journal of COPD. 9. 457–457. 24 indexed citations
17.
Stratchounski, L., Irina V. Andreeva, S. А. Ratchina, et al.. (2003). The Inventory of Antibiotics in Russian Home Medicine Cabinets. Clinical Infectious Diseases. 37(4). 498–505. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Péter Csonka Breakdown of academic impact, for papers by David Vyles Breakdown of academic impact, for papers by Jean Paradis Breakdown of academic impact, for papers by Michael G. Sherenian Breakdown of academic impact, for papers by Sally Eyers Breakdown of academic impact, for papers by R Wettengel Breakdown of academic impact, for papers by M. Morales Suárez-Varela Breakdown of academic impact, for papers by Komalkirti Apte Breakdown of academic impact, for papers by Maqbool Qadir Breakdown of academic impact, for papers by Peter Bremner
Rankless by CCL
2026